The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
Open accessAbstract
BACKGROUND: To further increase the efficacy of malaria vaccine RTS,S/AS02A, we tested the RTS,S antigen formulated using the AS01B Adjuvant System (GlaxoSmithKline Biologicals). METHODS: In a double-blind, randomized trial, 102 healthy volunteers were evenly allocated to receive RTS,S/AS01B or RTS,S/AS02A vaccine at months 0, 1, and 2 of the study, followed by malaria challenge. Protected vaccine recipients were rechallenged 5 months later. RESULTS: RTS,S/AS01B and RTS,S/AS02A were well tolerated and were safe. The efficacy of RTS,S/AS01B and RTS,S/AS02A was 50% (95% confidence interval [CI], 32.9%-67.1%) and 32% (95% CI, 17.6%-47.6%), respectively. At the time of initial challenge, the RTS,S/AS01B group had greater circumsporozoite protein (CSP)-specific immune responses, including higher immunoglobulin (Ig) G titers, higher numbers of CSP-specific CD4(+) T cells expressing 2 activation markers (interleukin-2, interferon [IFN]-gamma, tumor necrosis factor-alpha, or CD40L), and more ex vivo IFN-gamma enzyme-linked immunospots (ELISPOTs) than did the RTS,S/AS02A group. Protected vaccine recipients had a higher CSP-specific IgG titer (geometric mean titer, 188 vs 73 mug/mL; P < .001), higher numbers of CSP-specific CD4(+) T cells per 10(6) CD4(+) T cells (median, 963 vs 308 CSP-specific CD4(+) T cells/10(6) CD4(+) T cells; P < .001), and higher numbers of ex vivo IFN-gamma ELISPOTs (mean, 212 vs 96 spots/million cells; P < .001). At rechallenge, 4 of 9 vaccine recipients in each group were still completely protected. CONCLUSIONS: The RTS,S/AS01B malaria vaccine warrants comparative field trials with RTS,S/AS02A to determine the best formulation for the protection of children and infants. The association between complete protection and immune responses is a potential tool for further optimization of protection. Trial registration. ClinicalTrials.gov identifier NCT00075049.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insecticide-treated bed nets and curtains for preventing malaria
Lengeler, C. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000363.pub2 · Cited by 1,700
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major
Darrah, P. A., Patel, D. T., De Luca, P. M., Lindsay, R. W. B., Davey, D. F., Flynn, B. J., Hoff, S. T., Andersen, P., Reed, S. G., Morris, S. L., et al. (2007) · Nature Medicine · doi:10.1038/nm1592 · Cited by 1,378
Stoute, J. A., Slaoui, M., Heppner, D. G., Momin, P., Kester, K. E., Desmons, P., Wellde, B. T., Garçon, N., Krzych, U., Marchand, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360202 · Cited by 870
Self-citationAlonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Milman, J., Mandomando, I., Spiessens, B., Guinovart, C., Espasa, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17223-1 · Cited by 752
Self-citationBojang, K. A., Milligan, P. J., Pinder, M., Vigneron, L., Alloueche, A., Kester, K. E., Ballou, W. R., Conway, D. J., Reece, W. H., Gothard, P., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06957-4 · Cited by 528
Self-citationSAFETY AND EFFICACY OF A RECOMBINANT DNA PLASMODIUM FALCIPARUM SPOROZOITE VACCINE
Ripley Ballou, W., Hoffman, S. L., Sherwood, J. A., Hollingdale, M. R., Neva, F. A., Hockmeyer, W. T., Gordon, D. M., Schneider, I., Wirtz, R. A., Young, J. F., et al. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90540-x · Cited by 427
Self-citationEfficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
Bejon, P., Lusingu, J., Olotu, A., Leach, A., Lievens, M., Vekemans, J., Mshamu, S., Lang, T., Gould, J., Dubois, M.-C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807381 · Cited by 417
Self-citationAlonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Aide, P., Sigauque, B., Milman, J., Mandomando, I., Bassat, Q., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67669-6 · Cited by 412
Self-citationGordon, D. M., McGovern, T. W., Krzych, U., Cohen, J. C., Schneider, I., LaChance, R., Heppner, D. G., Yuan, G., Hollingdale, M., Slaoui, M., et al. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1576 · Cited by 327
Self-citationAponte, J. J., Aide, P., Renom, M., Mandomando, I., Bassat, Q., Sacarlal, J., Manaca, M. N., Lafuente, S., Barbosa, A., Leach, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61542-6 · Cited by 279
Self-citation
Cited by
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Key roles of adjuvants in modern vaccines
Reed, S. G., Orr, M. T., & Fox, C. B. (2013) · Nature Medicine · doi:10.1038/nm.3409 · Cited by 1,419
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
Seder, R. A., Chang, L.-J., Enama, M. E., Zephir, K. L., Sarwar, U. N., Gordon, I. J., Holman, L. A., James, E. R., Billingsley, P. F., Gunasekera, A., et al. (2013) · Science · doi:10.1126/science.1241800 · Cited by 761
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
Vaccine Adjuvants: from 1920 to 2015 and Beyond
Pasquale, A., Preiss, S., Silva, F., & Garçon, N. (2015) · Vaccines · doi:10.3390/vaccines3020320 · Cited by 648
Bache, E. B., Agnandji, S. T., Lell, B., Fernandes, J. F., Abossolo, B. P., Kabwende, A. L., Adégnika, A. A., Mordmüller, B. G., Kremsner, P. G., Loembé, M. M., et al. (2015) · The Lancet · doi:10.15496/publikation-6508 · Cited by 642
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Del Giudice, G., Rappuoli, R., & Didierlaurent, A. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.05.001 · Cited by 610
Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8 + T Cell Immunity
Epstein, J. E., Tewari, K., Lyke, K. E., Sim, B. K. L., Billingsley, P. F., Laurens, M. B., Gunasekera, A., Chakravarty, S., James, E. R., Sedegah, M., et al. (2011) · Science · doi:10.1126/science.1211548 · Cited by 533
Self-citationAdjuvant system AS01: helping to overcome the challenges of modern vaccines
Didierlaurent, A. M., Laupèze, B., Di Pasquale, A., Hergli, N., Collignon, C., & Garçon, N. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1213632 · Cited by 516
RTS,S/AS01 vaccine (Mosquirix™): an overview
Laurens, M. B. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1669415 · Cited by 491
The RTS, S. C. T. P. (. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001685 · Cited by 474
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
Neafsey, D. E., Juraska, M., Bedford, T., Benkeser, D., Valim, C., Griggs, A., Lievens, M., Abdulla, S., Adjei, S., Agbenyega, T., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505819 · Cited by 422
Self-citationProtection against malaria at 1 year and immune correlates following PfSPZ vaccination
Ishizuka, A. S., Lyke, K. E., DeZure, A., Berry, A. A., Richie, T. L., Mendoza, F. H., Enama, M. E., Gordon, I. J., Chang, L.-J., Sarwar, U. N., et al. (2016) · Nature Medicine · doi:10.1038/nm.4110 · Cited by 367
Feng, X., Xu, W., Li, Z., Song, W., Ding, J., & Chen, X. (2019) · Advanced Science · doi:10.1002/advs.201900101 · Cited by 363
Innate sensing of malaria parasites
Gazzinelli, R. T., Kalantari, P., Fitzgerald, K. A., & Golenbock, D. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3742 · Cited by 355
White, M. T., Verity, R., Griffin, J. T., Asante, K. P., Owusu-Agyei, S., Greenwood, B., Drakeley, C., Gesase, S., Lusingu, J., Ansong, D., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00239-x · Cited by 354
Malaria Vaccines: Recent Advances and New Horizons
Draper, S. J., Sack, B. K., King, C. R., Nielsen, C. M., Rayner, J. C., Higgins, M. K., Long, C. A., & Seder, R. A. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.06.008 · Cited by 331
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Van Mechelen, M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 314
Unmet needs in modern vaccinology
Leroux-Roels, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.021 · Cited by 304
Systems analysis of protective immune responses to RTS,S malaria vaccination in humans
Kazmin, D., Nakaya, H. I., Lee, E. K., Johnson, M. J., van der Most, R., van den Berg, R. A., Ballou, W. R., Jongert, E., Wille-Reece, U., Ockenhouse, C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621489114 · Cited by 293
Self-citationAdjuvants: Classification,Modus Operandi, and Licensing
Apostólico, J. D. S., Lunardelli, V. A. S., Coirada, F. C., Boscardin, S. B., & Rosa, D. S. (2016) · Journal of Immunology Research · doi:10.1155/2016/1459394 · Cited by 287
Nanotechnology applied to the treatment of malaria
Santos-Magalhães, N. S., & Mosqueira, V. C. F. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.024 · Cited by 286
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
Ewer, K. J., O’Hara, G. A., Duncan, C. J. A., Collins, K. A., Sheehy, S. H., Reyes-Sandoval, A., Goodman, A. L., Edwards, N. J., Elias, S. C., Halstead, F. D., et al. (2013) · Nature Communications · doi:10.1038/ncomms3836 · Cited by 286
Advances and challenges in malaria vaccine development
Crompton, P. D., Pierce, S. K., & Miller, L. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci44423 · Cited by 269
Didierlaurent, A. M., Collignon, C., Bourguignon, P., Wouters, S., Fierens, K., Fochesato, M., Dendouga, N., Langlet, C., Malissen, B., Lambrecht, B. N., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400948 · Cited by 266
Experimental human challenge infections can accelerate clinical malaria vaccine development
Sauerwein, R. W., Roestenberg, M., & Moorthy, V. S. (2011) · Nature Reviews Immunology · doi:10.1038/nri2902 · Cited by 267
Coccia, M., Collignon, C., Hervé, C., Chalon, A., Welsby, I., Detienne, S., van Helden, M. J., Dutta, S., Genito, C. J., Waters, N. C., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0027-3 · Cited by 260
Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine
Collins, K. A., Snaith, R., Cottingham, M. G., Gilbert, S. C., & Hill, A. V. S. (2017) · Scientific Reports · doi:10.1038/srep46621 · Cited by 253
Leroux-Roels, I., Leroux-Roels, G., Clement, F., Vandepapelière, P., Vassilev, V., Ledent, E., & Heineman, T. C. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis497 · Cited by 147
Suscovich, T. J., Fallon, J. K., Das, J., Demas, A. R., Crain, J., Linde, C. H., Michell, A., Natarajan, H., Arevalo, C., Broge, T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb4757 · Cited by 142
Design, recruitment, and microbiological considerations in human challenge studies
Darton, T. C., Blohmke, C. J., Moorthy, V. S., Altmann, D. M., Hayden, F. G., Clutterbuck, E. A., Levine, M. M., Hill, A. V. S., & Pollard, A. J. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00068-7 · Cited by 130
Prophylactic and therapeutic implications of toll-like receptor ligands
Hedayat, M., Takeda, K., & Rezaei, N. (2012) · Medicinal Research Reviews · doi:10.1002/med.20214 · Cited by 76
Havenar-Daughton, C., Carnathan, D. G., Boopathy, A. V., Upadhyay, A. A., Murrell, B., Reiss, S. M., Enemuo, C. A., Gebru, E. H., Choe, Y., Dhadvai, P., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.008 · Cited by 58
Metadata
- Authors
- Kester, K. E., Cummings, J. F., Ofori‐Anyinam, O., Ockenhouse, C. F., Krzych, U., Moris, P., Schwenk, R., Nielsen, R. A., Debebe, Z., Pinelis, E., Juompan, L., Williams, J., Dowler, M., Stewart, V. A., Wirtz, R. A., Dubois, M., Lievens, M., Cohen, J., Ballou, W. R., Heppner, Jr., & RTS, S. V. E. G.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08
- Volume
- 200
- Issue
- 3
- Pages
- 337-346
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2163861382
- Cited by
- 524
- References
- 26
- FWCI
- 32.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.